BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1222 related articles for article (PubMed ID: 18553904)

  • 1. Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-.
    Cebrián-Losantos B; Reisner E; Kowol CR; Roller A; Shova S; Arion VB; Keppler BK
    Inorg Chem; 2008 Jul; 47(14):6513-23. PubMed ID: 18553904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.
    Egger A; Arion VB; Reisner E; Cebrián-Losantos B; Shova S; Trettenhahn G; Keppler BK
    Inorg Chem; 2005 Jan; 44(1):122-32. PubMed ID: 15627368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isomeric [RuCl2(dmso)2(indazole)2] complexes: ruthenium(II)-mediated coupling reaction of acetonitrile with 1H-indazole.
    Reisner E; Arion VB; Rufińska A; Chiorescu I; Schmid WF; Keppler BK
    Dalton Trans; 2005 Jul; (14):2355-64. PubMed ID: 15995743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
    Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
    Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
    J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex.
    Hotze AC; van der Geer EP; Caspers SE; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    Inorg Chem; 2004 Aug; 43(16):4935-43. PubMed ID: 15285670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
    Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
    Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity.
    Ji L; Zheng W; Lin Y; Wang X; Lü S; Hao X; Luo Q; Li X; Yang L; Wang F
    Eur J Med Chem; 2014 Apr; 77():110-20. PubMed ID: 24631730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [Ru III/II Cl6-n(Azole)n]z(n = 3, 4, 6) complexes.
    Reisner E; Arion VB; Eichinger A; Kandler N; Giester G; Pombeiro AJ; Keppler BK
    Inorg Chem; 2005 Sep; 44(19):6704-16. PubMed ID: 16156629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity.
    Bratsos I; Serli B; Zangrando E; Katsaros N; Alessio E
    Inorg Chem; 2007 Feb; 46(3):975-92. PubMed ID: 17257042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectroscopic studies and structures of trans-ruthenium(II) and ruthenium(III) bis(cyanide) complexes supported by a tetradentate macrocyclic tertiary amine ligand.
    Wong CY; Lee FW; Che CM; Cheng YF; Phillips DL; Zhu N
    Inorg Chem; 2008 Nov; 47(22):10308-16. PubMed ID: 18850698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NO Releasing and Anticancer Properties of Octahedral Ruthenium-Nitrosyl Complexes with Equatorial 1 H-Indazole Ligands.
    Orlowska E; Babak MV; Dömötör O; Enyedy EA; Rapta P; Zalibera M; Bučinský L; Malček M; Govind C; Karunakaran V; Farid YCS; McDonnell TE; Luneau D; Schaniel D; Ang WH; Arion VB
    Inorg Chem; 2018 Sep; 57(17):10702-10717. PubMed ID: 30106571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.
    Wang F; Chen H; Parsons S; Oswald ID; Davidson JE; Sadler PJ
    Chemistry; 2003 Dec; 9(23):5810-20. PubMed ID: 14673852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel half-sandwich Ru(II)-hydroxamate complexes: synthesis, characterization and equilibrium study in aqueous solution.
    Buglyó P; Farkas E
    Dalton Trans; 2009 Oct; (38):8063-70. PubMed ID: 19771370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties.
    Cebrián-Losantos B; Krokhin AA; Stepanenko IN; Eichinger R; Jakupec MA; Arion VB; Keppler BK
    Inorg Chem; 2007 Jun; 46(12):5023-33. PubMed ID: 17497853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
    Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
    Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A regenerable ruthenium tetraammine nitrosyl complex immobilized on a modified silica gel surface: preparation and studies of nitric oxide release and nitrite-to-NO conversion.
    Doro FG; Rodrigues-Filho UP; Tfouni E
    J Colloid Interface Sci; 2007 Mar; 307(2):405-17. PubMed ID: 17196216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing ruthenium-acetylide bonding interactions: synthesis, electrochemistry, and spectroscopic studies of acetylide-ruthenium complexes supported by tetradentate macrocyclic amine and diphosphine ligands.
    Wong CY; Che CM; Chan MC; Han J; Leung KH; Phillips DL; Wong KY; Zhu N
    J Am Chem Soc; 2005 Oct; 127(40):13997-4007. PubMed ID: 16201822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
    Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
    J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.